12:00 AM
 | 
May 04, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dutasteride: Phase III data

Data from the placebo-controlled, double-blind, international Phase III REDUCE study in 8,121 men ages 50-70 and at increased risk for prostate cancer showed that 0.5 mg/day dutasteride met the primary endpoint of reducing the risk of all biopsy-detectable prostate cancer over 4 years...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >